Search This Blog

Monday, December 31, 2018

Miragen Therapeutics resumed with a Buy at B. Riley FBR


B. Riley FBR analyst George Zavoico resumed coverage of Miragen Therapeutics and kept his firm’s Buy rating and $18.50 price target on the shares.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)